Abbott companions with Weight Watchers to enhance diabetes administration

Abbott Laboratories and Weight Watchers are collaborating to help people with diabetes better understand their disease and manage their weight.

To that end, New York-based Weight Watchers will integrate its diabetes-tailored weight management program with Abbott’s FreeStyle Libre product portfolio.

The goal is for the combination to create a seamless mobile experience that gives people with diabetes the information and insights they need to make healthier diet adjustments, improve blood sugar levels, and ultimately gain more control over their health.

“We strive to put our customers at the heart of everything we do, and that includes building strategic partnerships with key industry leaders like Weight Watchers to deliver new services and offerings that can significantly improve the quality of life for people with diabetes,” said Jared Watkin, senior vice president of Abbott’s diabetes care business. “By combining our world-leading FreeStyle Libre glucose monitoring technology with Weight Watchers’ number one physician-recommended weight-loss program, people with diabetes, particularly those with type 2 diabetes who receive less intensive care from physicians, can gain the insights they… need to take control of their health.”

Abbott’s Freestyle Libre products are among the hottest products on the diabetes management market. The company was able to change the paradigm of diabetes management when it received FDA approval for the Freestyle Libre Flash glucose monitoring system in 2017.

The product was popular because it eliminated the need for routine finger sticks, which had been the standard for glucose testing for more than 40 years up to that point.

Abbott repeated its success around freestyle when it received clearance for the next generation of the device in 2020. The Freestyle Libre 2 iCGM was a step forward as it could be used for 14 days in adults and children over the age of four.

Earlier in June, Abbott announced that it had received FDA clearance for the Freestyle Libre 3 system. Abbott said the Libre 3 sensor is the smallest and thinnest on the market, the size of two stacked US cents.

The device won Bronze at the 2022 Medical Design Excellence Awards in the Digital Health Products and Mobile Medical Apps category.

During the company’s recent earnings conference call, Abbott Chairman and CEO Robert Ford spoke about the company’s success with the FreeStyle Libre portfolio.

“In diabetes care, FreeStyle Libre revenue grew more than 25% organically during the quarter, and our user base now exceeds four million users worldwide,” Ford said, according to a Motley Fool transcript of the conference call.

Comments are closed.